Human Metapneumovirus (hMPV) Therapeutics Market Report 2026

The human metapneumovirus (hmpv) therapeutics market size has grown strongly in recent years. It will grow from $0.7 billion in 2025 to $0.74 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to widespread incidence of respiratory viral infections, lack of specific approved antiviral therapies for hmpv, reliance on supportive and symptomatic treatment approaches, increased hospitalization of infants and elderly patients, growing awareness of viral lower respiratory tract infections.

The human metapneumovirus (hmpv) therapeutics market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising focus on developing virus-specific therapeutics, increasing investment in respiratory virus research, growing demand for effective treatments in immunocompromised populations, expansion of clinical trials for novel antiviral agents, increasing preparedness for seasonal respiratory virus outbreaks. Major trends in the forecast period include increasing focus on targeted antiviral therapies for respiratory viruses, rising demand for symptom-based management in pediatric and geriatric patients, growing emphasis on early intervention for high-risk populations, expansion of supportive care therapeutics for viral respiratory infections, increasing clinical research into novel hmpv treatment options.

The rising prevalence of respiratory infections is expected to drive growth in the human metapneumovirus (hMPV) therapeutics market in the coming years. Respiratory infections affect the respiratory tract, including the nose, throat, airways, and lungs. Increasing air pollution, particularly particulate matter and nitrogen dioxide, irritates and weakens the respiratory tract, making individuals more susceptible to infections. hMPV therapeutics are used to treat infections caused by human metapneumovirus by reducing viral replication and inflammation through antiviral treatments and supportive care, improving outcomes for vulnerable populations such as infants, the elderly, and immunocompromised patients. For example, in June 2024, the Australian Institute of Health and Welfare reported that Chronic Obstructive Pulmonary Disease (COPD) accounted for 3.6% of Australia’s total disease burden in 2023, representing 50% of the overall burden from respiratory conditions, with an estimated 638,000 people (2.5% of the population) living with COPD in 2022. Consequently, the increasing prevalence of respiratory infections is driving the hMPV therapeutics market.

Key players in the hMPV therapeutics market are focusing on developing targeted antiviral therapies, such as monoclonal antibodies, to effectively combat infections. Monoclonal antibodies (mAbs) are laboratory-engineered proteins that mimic the immune system’s natural ability to fight diseases by specifically binding to and neutralizing harmful antigens or cells. For instance, in October 2024, Vicebio Ltd., a UK-based biopharmaceutical company, raised $100 million in Series B financing, led by TCGX with participation from Goldman Sachs Alternatives and others, to advance its next-generation respiratory virus vaccines. The funding supports the Phase 1 clinical trial of VXB-241, a bivalent vaccine targeting RSV and hMPV, with initial results expected in mid-2025, and accelerates the development of VXB-251, a trivalent vaccine targeting RSV, hMPV, and Parainfluenza Virus 3, addressing significant respiratory disease burdens in older populations.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Icosavax, Inc., for $1.1 billion. This acquisition strengthens AstraZeneca’s vaccine and respiratory infection portfolio by integrating Icosavax’s virus-like particle (VLP) technology and its potential first-in-class combination vaccine candidate for RSV and hMPV. Icosavax, Inc., headquartered in the US, specializes in developing VLP vaccines, including the RSV-hMPV combination candidate.

Major companies operating in the human metapneumovirus (hmpv) therapeutics market are Pfizer Inc., Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Novartis AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, Bristol Myers Squibb Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bayer AG, CSL Limited, Regeneron Pharmaceuticals Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc, Vir Biotechnology Inc., Enanta Pharmaceuticals Inc.

North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human metapneumovirus (hmpv) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human metapneumovirus (hmpv) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the human metapneumovirus therapeutics market by increasing the cost of imported active pharmaceutical ingredients, formulation excipients, and specialized manufacturing equipment used in antiviral and supportive drug production. These impacts are more pronounced in branded and novel therapeutic development segments and in regions such as North America and Europe that rely on global pharmaceutical supply chains. Higher production costs may influence drug pricing and availability; however, tariffs are also encouraging local manufacturing, regional sourcing of raw materials, and investments in domestic pharmaceutical capabilities, supporting long-term supply resilience.

The human metapneumovirus (hmpv) therapeutics market research report is one of a series of new reports that provides human metapneumovirus (hmpv) therapeutics market statistics, including human metapneumovirus (hmpv) therapeutics industry global market size, regional shares, competitors with a human metapneumovirus (hmpv) therapeutics market share, detailed human metapneumovirus (hmpv) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the human metapneumovirus (hmpv) therapeutics industry. This human metapneumovirus (hmpv) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human metapneumovirus (hMPV) therapeutics refer to medical treatments and interventions designed to manage and alleviate symptoms caused by human metapneumovirus, a respiratory virus that primarily affects infants, the elderly, and immunocompromised individuals. These therapeutics function by inhibiting viral replication, preventing viral entry into host cells, and modulating the immune response to reduce inflammation and the severity of the disease.

The main drug classes for hMPV therapeutics include antipyretics, decongestants, cough suppressants, and other related categories. Antipyretics are substances that reduce fever by acting on the hypothalamus to lower the body’s temperature. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used in a variety of settings, including hospitals and clinics, diagnostic and reference laboratories, academic and research institutions, and other healthcare facilities.

The human metapneumovirus (hMPV) therapeutics market consists of revenues earned by entities providing services such as antiviral drug development, vaccine research, diagnostic testing, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus (hMPV) therapeutics market also includes sales of antiviral medications, immunotherapies, vaccines, and related diagnostic kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.